The Zepzelca (lurbinectedin) EPAR is the European Medicines Agency's (EMA) public assessment report on this medicine. Lurbinectedin is a drug whose trade name is Zepzelca. The document has the status "Opinion", which indicates that the EMA has issued an opinion on the medicine. The EPAR provides the public with information on the evaluation of Zepzelca. The report contains information about the benefits and risks of the medicine. The EPAR is intended to help patients and healthcare professionals make treatment decisions.